Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083 - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-term HIV Viral Suppression Achieved with Co-formulated Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir in a Patient with Transmitted Resistance to Dolutegravir and Lamivudine: Insights from HPTN 083 Case Study

  • By

  • Hannah P Moore

  • Jessica M Fogel

  • Mark A Marzinke

  • Elias K Halvas

  • Urvi M Parikh

  • John W Mellors

  • Kerri J Penrose

  • Michael Seisa

  • Christos Petropoulos

  • Amelia L Price

  • Amber Moser

  • Zhe Wang

  • Marybeth McCauley

  • Javier Valencia-Huamaní

  • Alex R Rinehart

  • James F Rooney

  • Lydia Soto-Torres

  • Beatriz Grinsztejn

  • Raphael J Landovitz

  • Susan H Eshleman

  • October 15, 2025

Share

  • 1

    A participant in the HPTN 083 trial achieved sustained HIV viral suppression using TDF, 3TC, and DTG despite transmitted resistance to these drugs.

  • 2

    Retrospective genotyping revealed major resistance mutations in the participant's virus, indicating multi-class resistance prior to ART initiation.

  • 3

    The participant's viral load decreased from over one million copies/mL to <40 copies/mL within 11 months of starting ART.

  • 4

    Pharmacologic testing showed that DTG concentrations were sufficient to overcome the effects of major INSTI resistance mutations.

  • 5

    This case highlights the potential for effective ART in patients with transmitted drug resistance, emphasizing the importance of individualized treatment.

Original Source(s)

Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083

  • by Hannah P Moore, Jessica M Fogel, Mark A Marzinke, Elias K Halvas, Urvi M Parikh, John W Mellors, Kerri J Penrose, Michael Seisa, Christos Petropoulos, Amelia L Price, Amber Moser, Zhe Wang, Marybeth McCauley, Javier Valencia-Huamaní, Alex R Rinehart, James F Rooney, Lydia Soto-Torres, Beatriz Grinsztejn, Raphael J Landovitz, Susan H Eshleman

  • October 15, 2025

Related Content

Successful use of outpatient parenteral antimicrobial therapy (OPAT) aztreonam–avibactam in a pediatric case of an infectious pseudoarthrosis caused by NDM-producing Klebsiella pneumoniae and Pseudomonas aeruginosa

Is “Against Medical Advice” Still Defensible?

A Viewpoint calls for more dignifying, harm-reduction–oriented hospital discharges for patients with OUD.

Blue LED Light Attenuates the Bacterial Bioburden in Chronic Wounds Transiently but Dose-Dependently